Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.91 USD | -2.64% | -6.93% | +25.74% |
Financials (USD)
Sales 2024 * | 450K | Sales 2025 * | 450K | Capitalization | 32.96M |
---|---|---|---|---|---|
Net income 2024 * | -18M | Net income 2025 * | -22M | EV / Sales 2024 * | 73.2 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 73.2 x |
P/E ratio 2024 * |
-1.81
x | P/E ratio 2025 * |
-3.36
x | Employees | 9 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.58% |
Latest transcript on Aprea Therapeutics, Inc.
1 day | +2.53% | ||
1 week | -6.62% | ||
Current month | -28.25% | ||
1 month | -16.51% | ||
3 months | +64.05% | ||
6 months | +51.00% | ||
Current year | +29.15% |
Managers | Title | Age | Since |
---|---|---|---|
Oren Gilad
CEO | Chief Executive Officer | 56 | 22-04-30 |
John Hamill
DFI | Director of Finance/CFO | 60 | 23-01-29 |
Zeev Weiss
PRN | Corporate Officer/Principal | 62 | 22-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bernd Seizinger
BRD | Director/Board Member | 67 | 14-12-31 |
John Henneman
BRD | Director/Board Member | 62 | 19-07-31 |
Rifat Pamukcu
BRD | Director/Board Member | 66 | 22-04-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 5.91 | -2.64% | 1 016 |
24-03-27 | 6.07 | +2.53% | 16,742 |
24-03-26 | 5.92 | -2.69% | 10,140 |
24-03-25 | 6.084 | -0.59% | 10,833 |
24-03-22 | 6.12 | -3.62% | 5,207 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.15% | 32.96M | |
+9.16% | 45.97B | |
+54.42% | 43.93B | |
+11.20% | 42.34B | |
-8.59% | 28.27B | |
+16.40% | 27.18B | |
-19.34% | 19.44B | |
+13.95% | 13.83B | |
+31.56% | 12.4B | |
+10.63% | 11.45B |